Hedge fund positioning has edged higher; the corresponding NVS stock price forecast views $104–$109 as plausible in the next quarter, supported by defensive earnings play. In terms of background, I don't know offhand how many patients were on a GLP-1 at baseline, but with all of these trials, we always have, of course, patients who are on standard of care for their various comorbidities. And then, of course, we would do subgroup analyses based on the various patient populations. Those would not be powered, of course, and would be post-hoc. But as always, we generate those force plots to demonstrate how different patient groups responded to the medicine. NVS stock has enjoyed a strong uptrend throughout 2025, but the technical setup suggests the stock may be due for a pause or pullback . Shares are currently trading at approximately $128, about 3.5% above the consensus analyst price target , which leaves limited near-term upside. Plus, there's a valuation risk with Novartis trading at a price-to-earnings (P/E) ratio around 15% higher than its historical average. Earnings revisions have sparked higher targets in NVS stock price forecast, with consensus moving from $100 to $108 amid upgraded long-term growth in cardiovascular and oncology segments.